(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
Trump announces 'Patriot Games' with 2 competitors from every state and territory: What we know- Washington resident contracts bird flu, first human case in U.S. since February
- Manual for Savvy Home Lighting Framework: Lights up Your Space
- Insight: Pills, TikTok, weight-loss apps and the consumer-driven future of GLP-1s
- Chemical leak in Oklahoma forces evacuations and leaves many ill
- NASA begins the countdown for humanity's first launch to the moon in 53 years
- Book excerpt: "Enough" by Dr. Ania Jastreboff and Oprah Winfrey
- Rio Tinto resumes operations at three Pilbara port terminals after cyclone Narelle
- Zendaya serves bridal-coded fashion with old, new and borrowed gowns for ‘The Drama’ press tour
